Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Frontage Holdings 14-Day RSI Related Terms
FGHQF vs VRTX, REGN, RVMD: 14-Day RSI Comparison
For the Biotechnology subindustry, Frontage Holdings's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Frontage Holdings 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Frontage Holdings's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Frontage Holdings's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Frontage Holdings (FGHQF) has a 14-Day RSI of 58.97 as of Jul. 30, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Frontage Holdings and its competitors. According to the industry distribution chart, Frontage Holdings ranks #1333 out of 1422 companies in the Biotechnology industry, placing it in the top 93.7%.
Is Frontage Holdings' 14-Day RSI too high?
Frontage Holdings' current 14-Day RSI is 58.97. The Biotechnology industry median 14-Day RSI is 42.84. Frontage Holdings' value of 58.97 is 37.7% above this industry median. Based on the distribution chart, Frontage Holdings ranks #1333 out of 1422 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Frontage Holdings has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Frontage Holdings' 14-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Frontage Holdings ranks #1333 out of 1422 companies for 14-Day RSI. This places Frontage Holdings in the lower half of its industry. The industry median 14-Day RSI is 42.84. Frontage Holdings' value of 58.97 is 37.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 42.84, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Frontage Holdings's current 14-Day RSI of 58.97 is 37.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Frontage Holdings and its competitors. For the Biotechnology industry, the median 14-Day RSI is 42.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Frontage Holdings's current 14-Day RSI is 58.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Frontage Holdings stock overvalued right now?
Based on GuruFocus' analysis, Frontage Holdings (FGHQF) is currently considered Significantly Undervalued. The stock's GF Value™ is $0.23, compared to a current price of $0.15 — trading 34.8% below its estimated fair value. The current 14-Day RSI is 58.97 and 37.7% above the Biotechnology industry median of 42.84. Frontage Holdings' overall GF Score™ is 67/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Frontage Holdings (FGHQF), the current 14-Day RSI is 58.97 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Frontage Holdings (FGHQF) Overvalued in 2026?
Based on GuruFocus' analysis, Frontage Holdings stock appears to be undervalued.
The current stock price of $0.15 is trading 34.8% below its estimated GF Value™ of $0.23.
GuruFocus considers Frontage Holdings to be Significantly Undervalued.
Key valuation signals for FGHQF:
14-Day RSI: 58.97
GF Value™: $0.23 vs. price of $0.15 (34.8% below fair value)
Industry Position: 37.7% above the Biotechnology median (#1333 of 1422)
No single metric tells the full story. See the FGHQF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Frontage Holdings Corp provides laboratory and related services to pharmaceutical and agrochemical companies. Its segments include North America and Europe segment, including drug discovery, drug development, pharmaceutical product development and laboratory testing in the USA, Canada and Europe; and PRC segment, including drug discovery, drug development, pharmaceutical product development and laboratory testing in the PRC. It derives majority of the revenue from North America and Europe segment. Geographically majority of the revenue is derived from USA and Canada.
67GF Score
Get the complete analysis for FGHQF
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FGHQF has been successfully added to your 
